


PI3K (Phosphoinositide 3-kinase)



PI3K Pan Inhibitors

LY294002	Inhibits PI3K/PI3K6/PI3Kβ, also inhibits PKC and DNA-PK.
Wortmannin	Inhibits PI3K irreversibly, also inhibits PLK and DNA-PK.
NVP-BKM120	Oral pan-class I PI3K inhibitor that penetrates the BBB.
3-Methyladenine	Inhibits Vps34 and PI3Ky, also inhibits autophagy.
BEZ235	Dual pan-class I PI3K and mTOR inhibitor.

Phosphatidylinositol 3 kinases (PI3Ks) are a family of lipid kinases that integrate signals from growth factors, cytokines and other environmental cues, translating them into intracellular signals that regulate multiple signaling pathways. These pathways control many physiological functions and cellular processes, which include cell proliferation, growth, survival, motility and metabolism.

In the absence of activating signals, p85 interacts with p110 and inhibits p110 kinase activity. Following receptor tyrosine kinase (RTK) or G protein-coupled receptor (GPCR) activation, class I PI3Ks are recruited to the plasma membrane, where p85 inhibition of p110 is relieved and p110 phosphorylates PIP2 to generate PIP3. The activated insulin receptor recruits intracellular adaptor protein IRS1. Phosphorylation of IRS proteins on tyrosine residues by the insulin receptor initiates the recruitment and activation of PI3K. PIP3 acts as a second messenger which promotes the phosphorylation of Akt at Thr308 by PDK-1. RTK activation can also trigger Ras-Raf-MEK-ERK pathway. Activated Akt, ERK and RSK phosphorylate TSC2 at multiple sites to inhibit TSC2-TSC1-TBC1D7, which is the TSC complex that acts as a GTPase-activating protein (GAP) for the small GTPase RHEB. During inhibition of the TSC complex, GTP-loaded RHEB binds the mTOR catalytic domain to activate mTORC1. Glycogen synthase kinase 3β (GSK-3β) activates the TSC complex by phosphorylating TSC2 at Ser1379 and Ser1383. Phosphorylation of these two residues requires priming by AMPK-dependent phosphorylation of Ser1387. Wnt signaling inhibits GSK-3β and the TSC complex, and thus activates mTORC1. mTORC2 is activated by Wnt in a manner dependent on the small GTPase RAC1. Akt activation contributes to diverse cellular activities which include cell survival, growth, proliferation, angiogenesis, metabolism, and migration. Important downstream targets of Akt are GSK-3, FOXOs, BAD, AS160, eNOS, and mTOR. mTORC1 negatively regulates autophagy through multiple inputs, including inhibitory phosphorylation of ULK1, and promotes protein synthesis through activation of the translation initiation promoter S6K and through inhibition of the inhibitory mRNA cap binding 4E-BP1.

PI3Kα Selective Inhibitors

BYL-719	HY-15244
A66	HY-13261
MU11117	HY-12285
GDC-0326	HY-101272

PI3Kβ Selective Inhibitors

GSK2636771	HY-15245
TGX-221	HY-10114
AZD 6482	HY-10344


PI3Kγ Selective Inhibitors

IPI549	HY-100716
AS-252424	HY-13532
CZC24832	HY-15294
CAY10505	HY-13530

PI3Kδ Selective Inhibitors

CAL-101	HY-13026
IPI-3063	HY-111510
TGR-1202	HY-12279
PI-3065	HY-12235

mTOR (Mammalian target of rapamycin)



First Generation mTOR Inhibitors

Rapamycin	HY-10219
Everolimus	HY-10218
Temsirolimus	HY-50910
Deforolimus	HY-50908

mTORC1/2 Selective Inhibitors

INK-128	HY-13328
Torin 1	HY-13003
PP 242	HY-10474
AZD-8055	HY-10422
AZD2014	HY-15247
KU-0063794	HY-50710

mTOR and PI3K Dual-Specificity Inhibitors

PI-103	Inhibitor of DNA-PK, PI3K (p110α) and mTOR.
BEZ235	Dual pan-class I PI3K and mTOR inhibitor.
XL765	Inhibitor of class I PI3K isoforms, mTOR, and DNA-PK.
GDC-0980	Orally bioavailable inhibitor of pan-class I PI3K, mTORC1 and mTORC2.
Bimiralis	Brain-penetrant, orally bioavailable inhibitor of pan-class I PI3K and mTOR.
LY3023414	Inhibitor of class I PI3K isoforms, mTOR, and DNA-PK.

mTOR Activator

MHY1485	HY-B0795
---------	----------


The mTOR signaling pathway integrates both intracellular and extracellular signals and serves as a central regulator of cell metabolism, growth, proliferation and survival. mTOR is the catalytic subunit of two distinct complexes called mTORC1 and mTORC2. mTORC1 comprises DEPTOR, PRAS40, RAPTOR, mLST8, mTOR, whereas mTORC2 comprises DEPTOR, mLST8, RICTOR, RICTOR, mSIN1, mTOR. Rapamycin binds to FKBP12 and inhibits mTORC1 by disrupting the interaction between mTOR and RAPTOR. mTORC1 negatively regulates autophagy through multiple inputs, including inhibitory phosphorylation of ULK1 and TFE8. mTORC1 promotes protein synthesis through activation of S6K and inhibition of 4E-BP1, and regulates glycolysis through HIF1α. mTORC2 inhibits FOXO1,3 through SGK and Akt. The complex also regulates actin cytoskeleton assembly through PKC and Rho kinase.

Growth factors: Growth factors can signal to mTORC1 through both PI3K-Akt and Ras-Raf-MEK-ERK axis. For example, ERK and RSK phosphorylate TSC2, and inhibit it.

Insulin Receptor: The activated insulin receptor recruits intracellular adaptor protein IRS1. Phosphorylation on tyrosine residues by the insulin receptor initiates the activation of PI3K. PIP3 acts as a second messenger which promotes the phosphorylation of Akt and triggers the Akt-dependent phosphorylation of TSC2. TSC2 is a heterotrimeric complex comprised of TSC1, TSC2, and TBC1D7, and functions as a GTPase activating protein (GAP) for the small GTPase Rheb, which directly binds and activates mTORC1.

Amino acids: Amino acids induce the movement of mTORC1 to lysosomal membranes, where the Rag GTPases, a complex named Ragulator, interact with the Rag GTPases, recruits them to lysosomes through a mechanism dependent on the lysosomal v-ATPase, and is essential for mTORC1 activation. In turn, lysosomal recruitment enables mTORC1 to interact with GTP-bound RHEB, the end point of growth factor. Cytosolic leucine and arginine signal to mTORC1 through a distinct pathway comprised of the GATOR1 and GATOR2 complexes.

GSK-3 (Glycogen synthase kinase 3)



GSK-3 Pan Inhibitors

CHIR-99021	Highly selective inhibitor of GSK-3α/β.
SB 216763	Selective ATP-competitive inhibitor of GSK-3α/β.
AR-A014418	Selective ATP-competitive inhibitor of GSK-3.
BIO	Specific, reversible and ATP-competitive GSK-3α/β inhibitor.
LY2090314	Selective GSK-3α/β inhibitor.


Glycogen synthase kinase 3 (GSK-3) is a multifunctional serine/threonine kinase found in all eukaryotes. GSK-3 is one of the few signaling mediators that play central roles in a diverse range of signaling pathways, including those activated by Wnt, PI3K, growth factors, cytokines, and ligands for G protein-coupled receptors. The PI3K pathway is known for regulating metabolism, cell growth, and cell survival. The PI3K activity is stimulated by diverse oncogenes and growth factor receptors. PI3K-mediated production of PIP3 leads to the activation of Akt. The activation of Akt leads to the phosphorylation of GSK-3, which is active in resting cells, but is inactivated by the phosphorylation. The GSK-3 has been linked to the regulation of an assembly of transcription factors, including β-catenin, NF-κB, c-Jun, CREB, and STAT. Thus, the altered activity of GSK-3 causes various effects on cytokine expression.

In the absence of Wnt signaling, β-catenin is phosphorylated by CK1 and GSK-3. This phosphorylation leads to recognition by β-TrCP, leading to the ubiquitination of β-catenin and degradation by the proteasome. Upon binding of a lipid-modified Wnt protein to the receptor complex, a signaling cascade is initiated. LRP is phosphorylated by CK1/CK2 and GSK-3, and Axin is recruited to the plasma membrane. The kinases in the β-catenin destruction complex are inactivated and β-catenin translocates to the nucleus to form an active transcription factor complex with TCF, leading to transcription of a large set of target genes.

GSK-3β Selective Inhibitors

TWS119	Inhibits GSK-3β selectively. Induces neurogenesis in ESCs.
Tideglusib	Irreversible non-ATP-competitive GSK-3β inhibitor.
Indirubin-3'-monoxime	Inhibits GSK-3β and other kinases.
CP21R7	Selective GSK-3β inhibitor.

MDM-2/p53



p53 Inhibitors

Pifithrin-α	Inhibitor of p53. Also an aryl hydrocarbon receptor agonist.
Pifithrin-μ	Inhibitor of binding of p53 to mitochondria. Inhibits HSP70.

p53 Activators

RITA	Binds to p53, blocks p53-HDM2 interaction and activates p53.
PRIMA-1	Re-activator of mutant p53.
Tenovin-1	p53 activator, protecting p53 from MDM2-mediated degradation.

MDM2 Inhibitors


RG7388	MDM2 inhibitor, blocking the binding of p53-MDM2.
Nutlin 3a	MDM2 antagonist. Active enantiomer of Nutlin-3.
AMG 232	Orally bioavailable piperidinone inhibitor of MDM2.
RG7112	Orally bioavailable MDM2 antagonist.
Serdemetan	HDM2 antagonist.

p53 is at the centre of biological interactions that translates stress signals into cell cycle arrest or apoptosis. Upstream signaling to p53 increases its level and activates its function as a transcription factor in response to a wide variety of stresses, whereas downstream components execute the appropriate cellular response.

Cell Stress: p53 induction by acute DNA damage begins when DNA double-strand breaks trigger activation of ATM, a kinase that phosphorylates the CHK2 kinase, or when stalled or collapsed DNA replication forks recruit ATR, which phosphorylates CHK1. p53 is a substrate for both the ATM and ATR kinases, as well as for CHK1 and CHK2, which coordinately phosphorylate p53 to promote its stabilization. These phosphorylation events are important for p53 stabilization, as some of the modifications disrupt the interaction between p53 and its negative regulators MDM2 and MDM4. MDM2 and MDM4 bind to the transcriptional activation domains of p53, thereby inhibiting p53 transactivation function, and MDM2 has additional activity as an E3 ubiquitin ligase that causes proteasome-mediated degradation of p53. Phosphorylation also allows the interaction of p53 with transcriptional cofactors, which is ultimately important for activation of target genes and for responses such as cell cycle arrest, DNA repair, apoptosis and senescence. Non-receptor tyrosine kinase c-Abl can also be activated by DNA damage. Then the JNK/p38 is activated and leads to p53 activation.

Oncogenic signaling: The response to oncogene activation depends on the binding of ARF to MDM2. ARF is normally expressed at low levels in cells. Inappropriately increased E2F or Myc signals, stemming from oncogene activation, leads to the increased expression of ARF, which inhibits MDM2 by blocking its E3 ubiquitin ligase activity, uncoupling the p53-MDM2 interaction, thereby segregating it from nucleoplasmic p53.

NF-κB




- NF-κB Related Inhibitors**
- SN50**
Cell permeable inhibitory peptide of NF-κB nuclear translocation.
 - PDTC**
Inhibits NF-κB, and suppresses IL-1β-induced NOS expression.
 - QNZ**
Inhibits NF-κB activation and TNF-α production.
 - JSH-23**
Inhibits nuclear translocation of NF-κB without affecting IκB degradation.
- IκB Related Inhibitors**
- BAY 11-7082**
Inhibits TNF-α-induced IκBα phosphorylation irreversibly.
 - BAY 11-7085**
Inhibits TNF-α-induced IκBα phosphorylation irreversibly.
- IKK Related Inhibitors**
- Amlexanox**
Inhibitor of TBK1 and IKKε.
 - ACHP**
Selective inhibitor for IKKβ and IKKα over NEMO, inhibiting NF-κB DNA binding activity.
 - TPCA-1**
Selective inhibitor of IKKβ.
 - BMS-345541**
Selective allosteric-site binding inhibitor of IKKβ and IKKα.
 - MLN1208**
Novel, ATP competitive, and selective IKKβ inhibitor.
 - BI605906**
Selective inhibitor of IKKβ.

NF-κB transcription factors are critical regulators of immunity, stress responses, apoptosis and differentiation. In mammals, there are five members of the transcription factor NF-κB family: RELA (p65), RELB and c-REL, and the precursor transcription factor NF-κB1 (p105) and NF-κB2 (p100), which are processed into p50 and p52, respectively. NF-κB transcription factors bind as dimers to κB sites in promoters and enhancers of a variety of genes and induce or repress transcription. NF-κB activation occurs via two major signaling pathways: the canonical and the non-canonical NF-κB signaling pathways.

The canonical NF-κB pathway is triggered by signals from a large variety of immune receptors, such as TNFR, TLR, and IL-1R, which activate TAK1. TAK1 then activates IκB kinase (IKK) complex, composed of catalytic (IKKα and IKKβ) and regulatory (NEMO) subunits, via phosphorylation of IKKβ. Upon stimulation, the IKK complex, largely through IKKβ, phosphorylates members of the inhibitor of κB (IκB) family, such as IκBα and members of the REL family (RELA or c-REL), whereas p105 associates with p50 or REL (RELA or c-REL). Upon phosphorylation by IKK, IκBα and p105 are degraded in the proteasome, resulting in the nuclear translocation of canonical NF-κB family members, which bind to specific DNA elements, in the form of various dimeric complexes, including RELA-p50, c-REL-p50, and p50-p50. Atypical, IKK-independent pathways of NF-κB induction also provide mechanisms to integrate parallel signaling pathways to increase NF-κB activity, such as hypoxia, UV and genotoxic stress.

The non-canonical NF-κB pathway is induced by certain TNF superfamily members, such as CD40L, BAFF and lymphotxin-β (LT-β), which stimulates the recruitment of TRAF2, TRAF3, cIAP1/2 to the receptor complex. Activated cIAP mediates K48 ubiquitylation and proteasomal degradation of TRAF3, which stabilizes and accumulation of the NF-κB-inducing kinase (NIK). NIK phosphorylates p100, triggering p100 processing, and leading to the generation of p52 and the nuclear translocation of p52 and RELB.

HDAC (Histone deacetylase)



- HDAC Pan Inhibitors**
- Trichostatin A (TSA)**
Reversible inhibitor of class I and II mammalian HDACs.
 - Vorinostat (SAHA)**
Orally bioavailable inhibitor of class I, II and IV HDACs.
 - Panobinostat**
Oral pan-HDAC inhibitor.
 - Mocetinostat**
Orally bioavailable inhibitor, targeting class I & IV HDAC.
- Class I HDAC Inhibitors**
- Entinostat** HY-12163
 - Romidepsin** HY-15149
 - CI-994** HY-50934
 - Valproic acid** HY-10585
- Class IIa HDAC Inhibitors**
- TMP195** HY-18361
 - TMP269** HY-18360
 - MCL1568** HY-16914
- HDAC3 Selective Inhibitor**
- RGFP966** HY-13909
- HDAC4 Allosteric Modulator**
- Tasquinimod** HY-10528
- HDAC6 Selective Inhibitors**
- ACY-1215** HY-16026
 - Tubacin** HY-13428
 - Tubastatin A** HY-13271
 - CAY10603** HY-18613
- HDAC8 Selective Inhibitor**
- PCI-34051** HY-15224

TCR, GPCR and HDAC II interaction: Diverse agonists act through G-protein-coupled receptors (GPCRs) to activate the PKC-PKD axis, CaMK, Rho, or MHC binding to antigens stimulates TCR to activate PKCθ, leading to phosphorylation of class II HDACs. Phospho-HDACs dissociate from MEF2, bind 14-3-3, and are exported to the cytoplasm through a CRM1-dependent mechanism. CRM1 is inhibited by leptomycin B (LMB). Release of MEF2 from class II HDACs allows p300 to dock on MEF2 and stimulate gene expression. Dephosphorylation of class II HDACs in the cytoplasm enables reentry into the nucleus.


TLR: TLR signaling is initiated by ligand binding to receptors. The recruitment of TLR domain-containing adaptor protein MyD88 is repressed by HDAC6, whereas NF-κB and MTA-1 can be negatively regulated by HDAC1/2/3 and HDAC2, respectively. Acetylation by HATs enhance MKP-1 which inhibits p38-mediated inflammatory responses, while HDAC1/2/3 inhibits MKP-1 activity. HDAC1 and HDAC6 repress, whereas HDAC6 promotes, IRF function in response to viral challenge. HDAC11 inhibits IL-10 expression and HDAC1 and HDAC2 represses IFNγ-dependent activation of the CIITA transcription factor, thus affecting antigen presentation.

IRNAR: IFN-α/β induce activation of the type I IFN receptor and then bring the receptor-associated JAKs into proximity. JAK adds phosphates to the receptor. STATs bind to the phosphates and then phosphorylated by JAKs to form a dimer, leading to nuclear translocation and gene expression. HDACs positively regulate STATs and PZLF to promote antiviral responses and IFN-induced gene expression.

Cell cycle: In G1 phase, HDAC, Retinoblastoma protein (RB), E2F and polypeptide (DP) form a repressor complex. HDAC acts on surrounding chromatin, causing it to adopt a closed chromatin conformation, and transcription is repressed. Prior to the G1-S transition, phosphorylation of RB by CDKs dissociates the repressor complex. Transcription factors (TFs) gain access to their binding sites and, together with the now unmasked E2F activation domain. E2F is then free to activate transcription by contacting basal factors or by contacting histone acetyltransferases, such as CBP that can alter chromatin structure.

The function of non-histone proteins is also regulated by HATs/HDACs. p53: HDAC1 impairs the function of p53. p53 is acetylated under conditions of stress or HDAC inhibition by its cofactor CREB binding protein (CBP) and the transcription of genes involved in differentiation is activated. HSP90: HSP90 is a chaperone that complexes with other chaperones, such as p23, to maintain correct conformational folding of its client proteins. HDAC6 deacetylates HSP90. Inhibition of HDAC6 would result in hyperacetylated HSP90, which would be unable to interact with its co-chaperones and properly lead to misfolded client proteins being targeted for degradation via the ubiquitin-proteasome system.

Caspase




- Caspase Pan Inhibitors**
- Z-VAD(OMe)-FMK**
Cell-permeable irreversible pan-caspase peptide inhibitor.
 - Q-VD-Oph**
Brain and cell permeable, irreversible pan-caspase peptide inhibitor.
 - BOC-D-FMK**
Cell-permeable irreversible pan-caspase inhibitor.
- Isoform Selective Inhibitors**
- VX-765**
Orally bioavailable Caspase-1 inhibitor.
 - Z-DEVD-FMK**
Cell-permeable irreversible inhibitor of Caspase-3.
 - Z-IETD-FMK**
Cell-permeable Caspase-8 inhibitor.
 - Ac-DEVD-CHO**
Inhibits Caspase-3 reversibly, less potent than other caspases.
- Procaspase Activator**
- PAC-1**
Procaspase-3 activator.

Upon binding to their cognate ligand, death receptors such as Fas and TRAILR can activate initiator Caspases (Pro-caspase 8 and Pro-caspase 10) through dimerization mediated by adaptor proteins such as FADD and TRADD. Active Caspase 8 and Caspase 10 then cleave and activate the effector Caspase 3, 6 and 7, leading to apoptosis. ROS/DNA damage and ER stress trigger Caspase 2 activation. Active Caspase 2 cleaves and activates Caspase 3 and initiates apoptosis directly.

Caspase 2, 8 and 10 can also cleave Bid, stimulate mitochondrial outer membrane permeabilization (MOMP) and initiate the intrinsic apoptotic pathway. Following MOMP mitochondrial intermembrane space proteins such as Smac and Cytochrome C are released into the cytosol. Cytochrome C interacts with Apaf-1, triggering apoptosome assembly, which activates Caspase 9. Active Caspase 9, in turn, activates Caspase 3, 6 and 7, leading to apoptosis. Mitochondrial release of Smac facilitates apoptosis by blocking the inhibitor of apoptosis (IAP) proteins.

Following the binding of TNF to TNFR1, TNFR1 binds to TRADD, which recruits RIPK1, TRAF2/5 and cIAP1/2 to form TNFR1 signaling complex I. Formation of the complex IIa and complex IIb is initiated either by RIPK1 deubiquitylation mediated by CYLD or by RIPK1 non-ubiquitylation due to depletion of cIAPs. The Pro-caspase 8 homodimer in complex IIa and complex IIb generates active Caspase 8. This active Caspase 8 in the cytosol then carries out cleavage reactions to activate downstream executioner caspases and thus induce classical apoptosis.

TNF Receptor (Tumor necrosis factor receptor)



- TNF-α Related Products**
- Lenalidomide**
TNF-α inhibitor. Cereblon binder.
 - Thalidomide**
TNF-α inhibitor. Cereblon binder.
 - Pomalidomide**
TNF-α and Cereblon inhibitor.
 - TIC10**
TRAIL inducer.
 - C 87**
TNF-α inhibitor.
 - R-7050** HY-110203
TNF-α Receptor Antagonist
- RIP Kinase Inhibitors**
- Necrostatin-1**
ATP-competitive, allosteric inhibitor of RIPK1, blocking necroptosis.
 - GSK872**
Selective RIPK3 inhibitor.
 - GSK2982772**
Orally bioavailable, ATP-competitive, RIPK1 inhibitor.
 - RIPA-56**
Highly selective inhibitor of RIPK1.

Following the binding of TNF to TNF receptors, TNFR1 binds to TRADD, which recruits RIPK1, TRAF2/5 and cIAP1/2 to form TNFR1 signaling complex I. TNFR2 binds to TRAF1/2 directly to recruit cIAP1/2. Both cIAP1 and cIAP2 are E3 ubiquitin ligases that add K63-linked polyubiquitin chains to RIPK1. The ubiquitin ligase activity of the cIAPs is needed to recruit the LUBAC, which adds M1-linked linear polyubiquitin chains to RIPK1. K63 polyubiquitylated RIPK1 recruits TAB2, TAB3 and TAK1, which activate signaling mediated by JNK, p38 and the IκB kinase complex. The IKK complex then transcribes NF-κB signaling, which leads to the activation of anti-apoptotic factors such as FLIP and Bcl-XL that promote cell survival.

The formation of TNFR1 complex IIa and complex IIb depends on non-ubiquitylated RIPK1. For the formation of complex IIa, ubiquitylated RIPK1 in complex I is deubiquitylated by CYLD. This deubiquitylated RIPK1 dissociates from the membrane-bound complex and moves into the cytosol, where it interacts with TRADD, FADD, Pro-caspase 8 and FLIP, to form complex IIa. By contrast, complex IIb is formed when the RIPK1 in complex I is not ubiquitylated owing to conditions that have resulted in the depletion of cIAPs. This non-ubiquitylated RIPK1 dissociates from complex I, moves into the cytosol, and assembles with FADD, Pro-caspase 8, FLIP, and RIPK3 (but not TRADD) to form complex IIb. For either complex IIa or complex IIb to prevent necroptosis, both RIPK1 and RIPK3 must be inactivated by the cleavage activity of the Pro-caspase 8-FLIP heterodimer or fully activated caspase 8. The Pro-caspase 8 homodimer generates active Caspase 8, which is released from complex IIa and complex IIb. This active Caspase 8 then activates downstream executioner caspases and thus induce classical apoptosis.

Formation of the complex IIc (necrosome) is initiated either by RIPK1 deubiquitylation mediated by CYLD or by RIPK1 non-ubiquitylation due to depletion of cIAPs, similar to complex IIb formation. Activated RIPK1 recruits numerous RIPK3 molecules. Activated RIPK3 phosphorylates and recruits MLKL, eventually leading to necroptosis.